Google DeepMind Unveils Next Generation of Drug Discovery AI Model

Google DeepMind logo is seen near computer motherboard in this illustration taken January 8, 2024. REUTERS/Dado Ruvic/Illustration/File Photo
Google DeepMind logo is seen near computer motherboard in this illustration taken January 8, 2024. REUTERS/Dado Ruvic/Illustration/File Photo
TT

Google DeepMind Unveils Next Generation of Drug Discovery AI Model

Google DeepMind logo is seen near computer motherboard in this illustration taken January 8, 2024. REUTERS/Dado Ruvic/Illustration/File Photo
Google DeepMind logo is seen near computer motherboard in this illustration taken January 8, 2024. REUTERS/Dado Ruvic/Illustration/File Photo

Google Deepmind has unveiled the third major version of its "AlphaFold" artificial intelligence model, designed to help scientists design drugs and target disease more effectively.
In 2020, the company made a significant advance in molecular biology by using AI to successfully predict the behavior of microscopic proteins.
With the latest incarnation of AlphaFold, researchers at DeepMind and sister company Isomorphic Labs – both overseen by cofounder Demis Hassabis – have mapped the behavior for all of life's molecules, including human DNA.
The interactions of proteins - from enzymes crucial to the human metabolism, to the antibodies that fight infectious diseases - with other molecules is key to drug discovery and development.
DeepMind said the findings, published in research journal Nature on Wednesday, would reduce the time and money needed to develop potentially life-changing treatments.
“With these new capabilities, we can design a molecule that will bind to a specific place on a protein, and we can predict how strongly it will bind,” Hassabis said in a press briefing on Tuesday.
“It's a critical step if you want to design drugs and compounds that will help with disease.”
The company also announced the release of the “AlphaFold server”, a free online tool that scientists can use to test their hypotheses before running real-world tests.
Since 2021, AlphaFold’s predictions have been freely accessible to non-commercial researchers, as part of a database containing more than 200 million protein structures, and has been cited thousands of times in others’ work.
DeepMind said the new server required less computing knowledge, allowing researchers to run tests with just a few clicks of a button.
John Jumper, a senior research scientist at DeepMind, said: “It’s going to be really important how much easier the AlphaFold server makes it for biologists – who are experts in biology, not computer science – to test larger, more complex cases."
Dr Nicole Wheeler, an expert in microbiology at the University of Birmingham, said AlphaFold 3 could significantly speed up the drug discovery pipeline, as "physically producing and testing biological designs is a big bottleneck in biotechnology at the moment".



Microsoft Relaxes Data Center Grip on OpenAI Amid $500 Bln Joint Venture 

A Microsoft logo is pictured on a store in the Manhattan borough of New York City, New York, US, Jan. 25, 2021. (Reuters) 
A Microsoft logo is pictured on a store in the Manhattan borough of New York City, New York, US, Jan. 25, 2021. (Reuters) 
TT

Microsoft Relaxes Data Center Grip on OpenAI Amid $500 Bln Joint Venture 

A Microsoft logo is pictured on a store in the Manhattan borough of New York City, New York, US, Jan. 25, 2021. (Reuters) 
A Microsoft logo is pictured on a store in the Manhattan borough of New York City, New York, US, Jan. 25, 2021. (Reuters) 

Microsoft on Tuesday said it has changed some key terms of a deal with OpenAI after the ChatGPT creator announced a joint venture with Oracle and Japan's SoftBank Group to build up to $500 billion of new AI data centers in the United States.

President Donald Trump gathered the leaders of the "Stargate" effort at the White House on Tuesday to announce the deal, saying it was intended to help keep the United States ahead of China and other rivals in the global AI race, using chips from Nvidia.

Since 2019, Microsoft has had arrangements with OpenAI that gave the Redmond, Washington-based company the exclusive right to build new computing infrastructure for OpenAI. Microsoft, in a blog post, said it has "approved OpenAI's ability to build additional capacity, primarily for research and training of models."

That opened the door for OpenAI to work with Oracle.

A person familiar with the deal said that Stargate is a joint venture structured as a new entity in which OpenAI has an equity stake, governance rights and operational control. It will have a separate board appointed by the founding members and its own CEO, this person said.

Microsoft, along with Nvidia and Arm, will be a "technology partner" in the new venture, but is not listed as an equity funder. SoftBank CEO Masayoshi Son is will be the entity's board chairman, according to a statement from OpenAI posted on social media site X.

But Microsoft said that it still retains the exclusive right to offer OpenAI's API - technology shorthand for application programming interface, which is the main way that software developers and business customers buy OpenAI's services. That means Oracle will not be able to host OpenAI's primary source of revenue.

Oracle did not immediately respond to a request for comment on Microsoft's statements.

Microsoft said it has "revenue sharing agreements that flow both ways" with OpenAI.

"The key elements of our partnership remain in place for the duration of our contract through 2030, with our access to OpenAI’s IP, our revenue sharing arrangements and our exclusivity on OpenAI’s APIs all continuing forward," Microsoft said.

Microsoft also said "OpenAI recently made a new, large Azure commitment that will continue to support all OpenAI products as well as training," referring to Microsoft's Azure cloud computing service.